Email this article CHANGES OF IMMUNE STATUS OF PATIENTS WITH DIFFERENT TYPES OF GLIAL TUMORS
- Authors: Chemodakova K.A.1, Martynov B.V.1, Sukhina I.A.1, Nikitin V.Y.1, Ivanov A.M.1
-
Affiliations:
- Military Medical Academy. CM. Kirova
- Issue: Vol 22, No 2-1 (2019)
- Pages: 629-631
- Section: ORIGINAL ARTICLES
- URL: https://rusimmun.ru/jour/article/view/241
- DOI: https://doi.org/10.31857/S102872210006996-0
- ID: 241
Cite item
Full Text
Abstract
The immune status of 58 patients with gliomaswas evaluated. Prior to surgical treatment in patients with low-grade gliomas was observed higher (p<0.05) the absolute number of total T-lymphocytes, Thelper cells and NK-cells compared to patients with high grade glioma. Postoperatively group grade II was observed explicit reduction in the number of CD3+, CD3+CD4+, CD3–CD56+ and increase in the population CD3+CD8+ cytotoxic T-lymphocytes. Reducing of the number of CD3–CD56+ lymphocytes in patients with diff use astrocytomas and anaplastic gliomas after surgical treatment, maybe, related to the migration of these cells into the area of surgical intervention. At the same time in patients with grade III, IV gliomas was revealed an increase of the absolute number of killer T-cells. In the group of grade IV also was recorded increase in the percentage of T-reg, having a suppressor function, which may indicate a breach of anti-tumor immune response and cause suppression of the cytotoxic response in patients with highgrade gliomas. Key words: glioma, low grade, high grade, immunophenotyping, immune status, T-lymphocytes, NK-cells>˂0.05) the absolute number of total T-lymphocytes, Thelper cells and NK-cells compared to patients with high grade glioma. Postoperatively group grade II was observed explicit reduction in the number of CD3+, CD3+CD4+, CD3–CD56+ and increase in the population CD3+CD8+ cytotoxic T-lymphocytes. Reducing of the number of CD3–CD56+ lymphocytes in patients with diffuse astrocytomas and anaplastic gliomas after surgical treatment, maybe, related to the migration of these cells into the area of surgical intervention. At the same time in patients with grade III, IV gliomas was revealed an increase of the absolute number of killer T-cells. In the group of grade IV also was recorded increase in the percentage of T-reg, having a suppressor function, which may indicate a breach of anti-tumor immune response and cause suppression of the cytotoxic response in patients with highgrade gliomas.
Keywords
About the authors
K. A. Chemodakova
Military Medical Academy. CM. Kirova
Author for correspondence.
Email: Larana@yandex.ru
Lecturer of Department of Neurosurgery,
St. Petersburg
Russian FederationB. V. Martynov
Military Medical Academy. CM. Kirova
Email: fake@neicon.ru
PhD, Professor Department of Neurosurgery,
St. Petersburg
Russian FederationI. A. Sukhina
Military Medical Academy. CM. Kirova
Email: fake@neicon.ru
Ph.D., Lecturer of Department of Clinical Biochemistry and Laboratory Diagnostics,
St. Petersburg
Russian FederationV. Yu. Nikitin
Military Medical Academy. CM. Kirova
Email: fake@neicon.ru
PhD, Head of Immunology Laboratories of the Center for Clinical Laboratory Diagnostics,
St. Petersburg
Russian FederationA. M. Ivanov
Military Medical Academy. CM. Kirova
Email: fake@neicon.ru
Corresponding Member of the Russian Academy of Sciences, PhD, Professor, Head of the Department of Clinical Biochemistry, Department of Clinical Biochemistry and Laboratory Diagnostics,
St. Petersburg
Russian FederationReferences
- Савченко А. Ю. Нарушение в системе иммунитета у больных глиомами головного мозга на дооперационном этапе / А. Ю. Савченко, Ю. В. Редькин, Н. С. Захарова // Проблемы нейрогенетики, ангионеврологии, нейротравматологии; Сб. науч. труд. Ивановской гос. мед. акад. – Иваново, 1999. – С. 113–117.
- Stupp R., Hegi M. E., Mason W. P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial // Lancet Oncol. – 2009. – Vol. 10, № 5. – Р.459–466.
- Старченко А. Л. Клиническая нейроиммунология хирургических болезней головного мозга / А. Л. Старченко. – СПб.: С.- Петербургское мед. изд-во, 2001. – 324 с. Чиркин В. В., Семенков В. Ф., Карандашов В. И.
- Шардаков В. И., Загоскина Т. П. Роль иммунной системы и ее оценка у онкологических больных. – Киров, 2000. 21 с. 5. Dutoit V., Migliorini D., Dietrich P. Y., Walker P. R. Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? // Front Oncol. – 2016. – Vol. 6. – Р. 1–18.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).